Trending

primary biliary cholangitis

Intercept shares dive after FDA safety alert on liver drug

Intercept shares dive after FDA safety alert on liver drug

Regulator warns of death risk in patients on higher than recommended dose.

X

Intercept shares dive after FDA safety alert on liver drug

https://pharmaphorum.com/news/intercept-shares-fda-safety/

Intercept’s liver drug gets green light from NICE

Intercept’s liver drug gets green light from NICE

NHS patients to get access to drug in PBC.

X

Intercept’s liver drug gets green light from NICE

https://pharmaphorum.com/news/intercepts-liver-drug-nice/

EU regulator recommends Intercept’s potential liver blockbuster

EU regulator recommends Intercept’s potential liver blockbuster

Sales forecast to reach $2.6 billion in 2020.

X

EU regulator recommends Intercept’s potential liver blockbuster

https://pharmaphorum.com/news/eu-regulators-back-intercepts-potential-liver-blockbuster/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com